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Abstract
Herpes simplex virus 1 (HSV-1) causes herpes stromal keratitis (HSK), a sight-threatening disease of the cornea for which no
vaccine exists. A replication-defective, HSV-1 prototype vaccine bearing deletions in the genes encoding ICP8 and the virion
host shutoff (vhs) protein reduces HSV-1 replication and disease in a mouse model of HSK. Here we demonstrate that
combining deletion of ICP8 and vhs with virus-based expression of B7 costimulation molecules created a vaccine strain that
enhanced T cell responses to HSV-1 compared with the ICP8
2vhs
2 parental strain, and reduced the incidence of keratitis
and acute infection of the nervous system after corneal challenge. Post-challenge T cell infiltration of the trigeminal ganglia
and antigen-specific recall responses in local lymph nodes correlated with protection. Thus, B7 costimulation molecules
expressed from the genome of a replication-defective, ICP8
2vhs
2 virus enhance vaccine efficacy by further reducing HSK.
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Introduction
Herpes simplex virus 1 (HSV-1) infections are ubiquitous in the
population world-wide and in the United States, where seroprev-
alence is 65% by age 50 [1]. HSV-1 remains a frequent cause of
eye infections, afflicting up to 500,000 persons each year in the
United States [2,3]. Periodic HSV-1 reactivations instigate
recurrent infection of the cornea, resulting in immunopathologic
damage and HSK. For some, corneal scarring leads to loss of
vision; HSK is the second most common cause of non-traumatic
corneal blindness [3]. Development of an effective vaccine against
HSV-1 would help control or prevent this sight-threatening
disease.
Effective control of HSV infection depends on the antiviral T
cell response. Activation of naı ¨ve T cells requires three signals: T
cell receptor engagement of the appropriate antigen/MHC
molecule, interaction of CD28 with B7-1 and B7-2 costimulation
molecules, and cytokines that drive T cell differentiation. Antiviral
vaccines must elicit or provide these signals in order to induce
strong cell-mediated immunity. Glycoprotein, peptide, or plasmid-
based vaccines can decrease corneal shedding of HSV-1 and
reduce the severity of HSK [4–7]. DNA vaccines provide antigen
to T cells, and induce costimulation molecule expression due to
inherent CpG motifs. Nevertheless, repeated vaccinations are
usually required to achieve protection. Similarly, viral glycopro-
teins or peptide epitopes provide only antigen, so they require
mixture with adjuvant to supply the ‘‘danger signals’’ necessary to
elicit costimulation and cytokines. Vaccine preparations consisting
of or encoding multiple glycoproteins are more potent than a
single glycoprotein [8], indicating the benefits of a multivalent
vaccine. Attenuated, replication-competent viruses as vaccines
naturally stimulate responses to multiple epitopes and also supply
the necessary danger signals by virtue of their similarity to wild-
type virus infection. Neuroattenuated mutants of HSV-1 success-
fully reduce viral replication and HSV-mediated corneal disease in
mice [9–11]. However, attenuated HSV-1 can still be amplified
10,000-fold in tissue culture [9], and can develop adventitious
mutations [12], raising safety concerns about replication-compe-
tent agents as vaccines.
To address the needs for both safety and immunogenicity in a
vaccine, replication-defective viruses have also been explored as
mimetics of virus infection to prevent HSV-1 infection and eye
disease [13,14]. HSV-1 strains made replication-defective by
disruption of the UL29 gene encoding ICP8, essential for viral
DNA replication, have shown promise in a mouse model of
corneal infection. A single immunization with ICP8
2 virus reduces
HSV-1 replication in the cornea after challenge, acute and latent
infection of the trigeminal ganglia (TG), and incidence of HSK
[14]. ICP8
2 replication-defective HSV-1 induces T cell prolifer-
ative and cytolytic responses [14,15]. CD8
+ T cells appear to
protect against immunopathologic damage to the cornea following
HSV infection [16,17], while CD4
+ T cells reduce virus replication
in the cornea and latent infection in the TG [16].
Despite these benefits, virus-encoded immunomodulators may
diminish the strength of immune stimulation with an ICP8
2 HSV-
1. For example, the virion host shutoff (vhs) protein encoded by
UL41 helps HSV evade both innate and adaptive immunity [18–
21]. Indeed, deletion of vhs from an ICP8
2 HSV-1 vaccine
increases the virus’ capacity to protect mice against replication,
disease and latency after corneal challenge with HSV-1 [22].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22772Suboptimal immune stimulation with replication-defective virus
may also occur if contact with professional antigen presenting cells
(APCs) is limited. The increased severity of HSV infections in mice
lacking B7-1 and B7-2 costimulation molecules (B7KO) testifies to
the importance of costimulation in development of HSV-specific
immunity [23]. We have previously demonstrated that vaccination
with replication-defective HSV-2 encoding B7-1 or B7-2 from
within the viral genome partially restores protective immune
responses against HSV-2 to B7-1/B7-2
2/2 (B7KO) mice [24]. B7-
2-expressing, replication-defective HSV-2 also affords wild-type
mice better protection against HSV-2 infection than does the
parental replication-defective virus [25], even though wild-type
mice express endogenous B7 molecules.
Thus, we had previously shown that deletion of vhs from a
replication-defective HSV-1 improves its protective efficacy as a
vaccine, and that addition of B7 coding capacity to a replication-
defective HSV-2 improves its effectiveness as a vaccine. In
the current study we constructed an HSV-1 mutant containing
the vhs deletion and encoding B7 costimulation molecules
(ICP8
2vhs
2B7
+ HSV-1) to determine whether the effects of vhs
deletion and B7 insertion would be additive and so create a more
promising HSV-1 vaccine candidate.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol and study was approved by the Committee on the Care
and Use of Animals of Saint Louis University (NIH assurance
number A3225-01; Institutional protocol number 1136). All
procedures were conducted in a manner to minimize suffering.
Cells and viruses
The replication-defective mutant of HSV-1 KOS, D41D29 [22],
has defects in expression of vhs and the essential gene product
ICP8 due to insertion of a nonsense linker in the UL41 open
reading frame (ORF) at amino acid position 238 [26] and
disruption of the UL29 ORF due to insertion of a lacZ expression
cassette, respectively. D41D29 was propagated in S2 cells, a Vero
cell line stably expressing ICP8 [27]. D41D29 was further mutated
to contain a murine B7-1 (CD80) or B7-2 (CD86) expression
cassette. The CD80 and CD86 ORFs, cloned downstream of the
HCMV immediate early enhancer/promoter in plasmids
pBS(HCMV/B7-1) and pEH48(HCMV/B7-2) [24] were excised
and inserted into a BglII site previously engineered 751 bp from
the 59 end of the thymidine kinase (tk) (UL23) ORF in plasmid
p101086.7BglII (Dorne Yager and Don Coen, unpublished).
These plasmids were cotransfected with full-length D41D29 DNA
into S2 cells using nucleofection (Amaxa Biosystems), according to
the manufacturer’s protocol. To select B7-expressing recombinant
viruses, S2 cells infected with virus progeny of the cotransfection
were incubated in the presence of 100 mM acyclovir. Potential
recombinant viruses capable of growing in the presence of
acyclovir were grouped in pools. Fresh cells infected with each
pool were screened by flow cytometry for expression of B7
molecules (see below). Isolates from positive pools were individ-
ually re-screened by flow cytometry and then plaque-purified to
homogeneity. Insertion into the tk locus was confirmed by
Southern blot analysis. The B7-1- and B7-2-expressing viruses
were named D41D29B7-1 and D41D29B7-2, respectively. Viruses
used for immunizations were produced free of cell debris by
isolation from the supernatant of infected cell monolayers using
high speed centrifugation as previously described [28]. HSV-1
strain microplaque (mP) [29] was propagated in Vero cells. Virus
titers were determined on S2 or Vero cells by standard plaque
assay [30].
Mice
Female BALB/c mice (H-2
d) were purchased from the National
Cancer Institute. Female BALB.B mice (H-2
b) were purchased
from The Jackson Laboratories. Female B7KO mice [31],
backcrossed onto a BALB/c background, were bred at Saint
Louis University and housed in sterile microisolator cages. All
mice were housed at Saint Louis University under specific-
pathogen-free conditions and were used at 6 wk of age.
Southern blot hybridization
Viral DNAs were purified from potential recombinant viruses
using a Qiagen QIAamp DNA Mini Kit according to the
manufacturer’s instructions. One mg of each DNA sample was
subjected to EcoRI restriction digestion, and fragments were
separated on a 0.8% agarose gel. DNA fragments were transferred
to Hybond-N+ nylon membrane (Amersham) by capillary
diffusion and hybridized to a randomly primed, [
32P]-labeled SacI
fragment of plasmid p101086.7 used as a probe. Images were
obtained on X-ray film by autoradiography.
Flow cytofluorometric analyses
S2 cells infected with potential recombinant plaque isolates were
stained 24 hr later by addition of anti-B7-1 or B7-2-biotin (1:150;
PharMingen/Becton-Dickinson), followed by streptavidin-FITC
(1:150; Immunotech) and analyzed by flow cytometry on a
FACSCalibur. For demonstration of B7 expression by D41D29B7-
1 and D41D29B7-2, S2 cells were stained 24 hr after infection at
moi of 5 by addition of anti-B7-1 or B7-2 biotin and streptavidin-
FITC, and with anti-HSV-1 rabbit antiserum (1:100; Dako)
followed by goat anti-rabbit-phycoerythrin (PE) (1:100; Vector
Laboratories).
For intracellular cytokine staining of CD4
+ T cells, groups of
BALB.B mice were immunized subcutaneously (s.c.) in the hind
flanks with 4610
5 pfu of virus or control supernatant. After 6 d
draining lymph nodes were removed and single cell suspensions
were made. Cells were cultured for 4 hr in the presence of phorbol
myristate acetate (PMA; 50 ng/ml), calcium ionophore A23187
(CaI; 1 mg/ml), and GolgiStop (0.67 ml/ml; PharMingen). Cells
were treated with Fc block, followed by anti-CD3-PerCP and anti-
CD4-Pacific Blue, then were fixed and permeabilized using a
cytostain kit (PharMingen), and stained with anti-IFNc-PE. T cells
were analyzed by flow cytometry using an LSRII (Becton
Dickinson) and FloJo 8.0 software.
ELISpot
Groups of BALB.B mice were immunized with 4610
5 pfu of
the various vaccine strains or an equivalent amount of control
supernatant suspended in 40 ml total vol of normal saline. For
acute immune responses, paraaortic and inguinal lymph nodes
were removed 6 d later and dilutions of 1610
5 to 1.5610
4 cells
from individual mice were added per well in duplicate to
Milliscreen-HA plates (Millipore) previously coated with antibody
to IFNc (BD Pharmingen). HSV-1 gB peptide 498–505 [32,33]
was added to the cultures at 0.2 mM. Alternatively, groups of
BALB/c mice were immunized as above and paraaortic and
inguinal lymph node cells were cultured at concentrations of
1610
6 to 1610
5 cells per well along with UV-inactivated HSV-1
virions (equivalent to 1610
5 pfu prior to inactivation). After
Vaccine to Prevent Herpes Keratitis
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cells and captured IFNc was detected using a biotinylated anti-
IFNc antibody (BD Pharmingen), followed by streptavidin
conjugated to alkaline phosphatase (BDPharmingen) and BCIP-
NBT substrate (Sigma). Spots were counted using an Immunospot
plate reader (v. 5.0; Cellular Technology, Ltd.). Assays of recall
response to corneal challenge were similar except that mice were
immunized with 4610
4 pfu of virus or control supe, and cervical
lymph nodes were removed 4 d post-challenge. Dilutions of 2610
5
to 6610
4 cells from individual mice were added to wells containing
gB498–505 peptide, and dilutions of 1610
6 to 2610
5 cells were
added to wells containing UV-inactivated HSV-1.
In vitro assessment of the effects of B7-2 expression
For preparation of dendritic cells (DCs), bone marrow harvested
from B7KO mice was differentiated in vitro by incubation for 7 d in
RPMI containing 10% FCS, 1% L-glutamine, 40 ng/ml recom-
binant mouse GMCSF and 10 ng/ml recombinant mouse IL-4.
Eighteen hr before the end of culture, cells were left uninfected or
were infected with D41D29 or D41D29B7-2 at moi of 5, washed
and returned to culture at 4610
4 to 8610
4 cells/well in a 96-well
flat-bottom plate. Representative wells were analyzed by flow
cytometry using Fc block followed by fluorophore-conjugated
antibodies to CD3, CD11b, CD11c, MHC class II, and CD86.
For isolation of CD4
+ T cells, mononuclear cells were isolated
from the spleens of DO-11.10 mice [specific for an epitope of
chicken ovalbumin (OVA) presented on I-A
d] using lymphocyte
separation medium (ICN). T cells were enriched by negative
selection using a Pan T cell isolation kit II (Miltenyi Biotec),
according to the manufacturer’s instructions. Purity of T cell
preparations was verified by flow cytometric analysis of an aliquot
using Fc block followed by anti-CD3-APC and anti-CD4-
Alexa700, as well as PE-labeled antibodies to CD19, CD11b,
CD11c, MHC class II, and CD86. Remaining T cells were
cultured (2 to 2.5610
5/well) with D41D29- or D41D29B7-2-
infected DCs or uninfected DCs in medium alone or containing
200 mg/ml OVA. Cultures were incubated for 3 d, and then
CD3
+CD4
+ T cells were analyzed for forward scatter by flow
cytometry.
IL-2 assay
IL-2 content in 50 ml of T:DC culture supernatants collected
66 hr after addition of T cells to APCs was assayed on CTLL by
standard MTT assay [34]. Briefly, CTLL cells (5610
3/well) were
washed twice and placed in culture in RPMI+10% FCS, to which
was added dilutions of IL-2 (for standard curve) or T cell culture
supernatants. After 48 hr of culture MTT substrate was added and
4 hr later absorbance at 490 nm was measured on a BioRad 680
reader.
Quantitation of serum antibodies
To determine the titer of HSV-specific serum antibodies
induced by vaccine, mice were immunized with vaccine virus or
control supernatant. Blood was collected from the tail vein of mice
21 d after immunization. Serum was prepared by clot retraction
and analyzed by ELISA as previously described [35]. Anti-mouse-
IgG-biotin (R & D Systems, Minneapolis, MN) was used as
secondary antibody and detected using streptavidin-HRP followed
by OPD substrate (Sigma, St. Louis, MO). Alternatively, anti-
mouse-IgG1-HRP and -IgG2a-HRP (SouthernBiotech) were used.
Plates were read at 490 nm on a BioRad 680 reader. Antibody
concentrations were determined by comparison to standard curves
generated with serum containing known concentrations of IgG
captured on plates coated with goat-anti-kappa light chain
antibody (Caltag) as previously described [35].
Immunization of mice for vaccine efficacy studies
Hind flanks of mice were injected s.c. with 4610
5 pfu (high),
4610
4 pfu (medium), or 4610
3 pfu (low) doses of D41D29,
D41D29B7-1, D41D29B7-2 suspended in 40 ml total vol. Cohorts
of mice received an equivalent amount of supernatant concen-
trated from uninfected cell cultures as a negative control for
immunization.
In vivo challenge
Four wk after immunization, mice were anesthetized by
intraperitoneal injection of ketamine/xylazine, and infected with
5 ml HSV-1 mP inoculated onto each scarified cornea for a dose of
8610
5 pfu/mouse. To measure virus replication in the corneal
epithelium, eyes were swabbed with moistened cotton-tipped
swabs at 4 hr and days 1 through 5 post-infection. Swabs for each
mouse were placed together in 1 ml PBS and stored frozen until
assay. Virus was quantified on Vero cell monolayers by standard
plaque assay. After challenge, signs of disease and survival were
monitored on a daily basis. Blepharitis scores were assigned in
masked fashion based on the following scale: 0, no apparent signs
of disease; 1, mild swelling and erythema of the eyelid; 2, moderate
swelling and crusty exudate; 3, periocular lesions and depilation;
and 4, extensive lesions and depilation. Mean daily disease score
was calculated for each group. Keratitis was assessed at 9 d and
14 d post-challenge using an ophthalmoscope and scored in
masked fashion based on the following scale: 0, no apparent signs
of disease; 1, mild opacity; 2 moderate opacity with discernible iris
features; 3, dense opacity; 4, dense opacity with ulceration. Virus
replication in neural tissue was analyzed by dissection of TG and
brainstems from a cohort of mice 3 d or 5 d after challenge.
Tissues were stored frozen until use. For virus titer determination,
tissues were thawed and disrupted using a Mini-Bead Beater
(BioSpec, Inc.), and then diluted for standard plaque assay.
Isolation of T cells in the trigeminal ganglia
Mononuclear cells were isolated from TG of immunized or
control BALB/c mice 4 d post-challenge as previously described
[36]. Briefly, the 2 TG from each mouse were dissected and
pooled (pooling was necessary to isolate sufficient cells from naı ¨ve
animals). The tissue was minced and incubated for 1 hr at 37uCi n
a solution of 400 U/ml collagenase type I (Sigma) in DME
containing 10% FCS. TG were dissociated by tituration and
washed, resuspended in medium, and suspended material was
passed through a cell strainer (70 mm). Cells were then treated with
Fc block, stained with antibodies to CD3, CD4 and CD8 and
analyzed by flow cytometry.
Assessment of latency by real-time PCR
The 2
(DDCt) method [37,38] was used to compare relative
amounts of latent viral DNA in TG after detection by real-time
PCR. TG were collected 30 d post-challenge from mice that had
received the medium dose of vaccine, and were stored at 280uC.
DNA was isolated from the TG using a QIAamp DNA Mini Kit
(Qiagen) according to the manufacturer’s instructions. PCR
reactions were run in 25 ml reaction vol using FastStart SYBR
Green Master (Rox) (Roche), and primers at 300 nM final
concentration. For GAPDH, reactions used 10 ng template
DNA and primers forward 59-GAGTCTACTGGCGTCTT-
CACC-39 and reverse 59-ACCATGAGCCCTTCCACAATGC-
39 which amplify a 337 bp product. For HSV-1 UL50, reactions
Vaccine to Prevent Herpes Keratitis
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GCACGTATGTGCGTTTGTTGTTTAC-39 and reverse 59-
TTCCTGGGTTCGGCGGTTGAGTC-39 which amplify a
195 bp product. Reactions were performed using an ABI Prism
7500 real-time PCR system (Applied Biosystems) and cycle
conditions: 2 min at 50uC, 5 min at 95uC, 40 cycles of 95uC for
15 sec and 60uC for 1 min. Specificity was verified by melting
curve analysis. The average of duplicate wells yielded the Ct value,
and the UL50 signal for each sample was normalized to the
GAPDH signal content by determination of DCt. Fold decrease in
UL50 content of TG from D41D29B7-1 or D41D29B7-2-
immunized mice relative to mice receiving D41D29 was
determined using the 2
(DDCt) method [37,38].
Statistics
Significance of difference in virus titers in the cornea on
individual days was determined by Student’s t test. The Kruskal-
Wallis non-parametric test was used to assess the significance of
difference in blepharitis scores on individual days post-challenge.
Differences in T cell responses, keratitis scores, virus titer in the
nervous system, and relative levels of latent viral DNA were
compared using one way analysis of variance (ANOVA). Each
group immunized with D41D29 was compared with D41D29B7-1
or D41D29B7-2 using the Bonferroni post hoc test.
Results
In vitro characterization
To construct B7-expressing viruses, cDNAs encoding murine B7-
1 and B7-2 driven by the HCMV IEp were inserted into the HSV-1
thymidine kinase (tk) ORF 751 bp from the 59 ATG in plasmid
p101086.7BglII. The resulting plasmids were cotransfected into S2
cells with full-length DNA from the replication-defective HSV-1
strain D41D29 [22], which contains a lacZ insertion in the ICP8
ORF and a nonsense linker in the vhs ORF (Figure 1A). Plaques
were isolated from the cotransfection mixture in the presence of
acyclovir because the recombinant viruses are functionally impaired
for tk activity. Cells infected with the plaque isolates were screened
for expression of B7 molecules by flow cytometry. B7-1- and B7-2-
expressing recombinants were triply plaque-purified and named
D41D29B7-1 and D41D29B7-2, respectively. Southern blot analysis
was used to verify insertions into the tk locus in D41D29B7-1 and
D41D29B7-2 (Figure 1B). Genomic DNAs purified from the
D41D29 parental and potential recombinant viruses were restricted
with EcoRI, electrophoresed, transferred to membrane, and
hybridized to a
32P-labeled fragment of p101086.7BglII DNA.
The Southern blot of D41D29 showed a single fragment of expected
size (2.4 kb; Figure 1B, lane 1), and single fragments of expected
sizes 3.2 kb and 2.9 kb for the B7-1 and B7-2-containing viruses,
respectively (Figure 1B, lanes 2 and 3).
Figure 1. Construction and characterization of B7-expressing
viruses. (A) The genomic position of the tk ORF is shown on line 1. An
expanded view of this region (line 2) shows the location of EcoRI
restriction enzyme sites. Line 3 shows the insertion cassette containing
t h eH C M VI E pf u s e dt oe i t h e rt h eB 7 - 1( D41D29B7-1) or B7-2
(D41D29B7-2) ORF, each of which contains an EcoRI site near the
carboxyl terminus. B) Southern blot analysis of the tk locus. Genomic
DNAs isolated from the D41D29 parental and recombinant viruses were
digested with EcoRI, subjected to electrophoresis, and transferred to
membrane. The blot was hybridized to a
32P-labeled fragment of
p101086.7 DNA. The expected sizes of the EcoRI fragments were
2416 bp for D41D29 (lane 1), 3242 bp for B7-1 virus (lane 2), and
2923 bp for B7-2 virus (lane 3). C) B7 molecule expression on the
surface of cells infected in vitro with D41D29B7-1 or D41D29B7-2. S2 cell
monolayers were mock-infected or infected with the indicated virus at
moi of 5, then collected and stained 24 hr later with rabbit anti-HSV-2
followed by goat anti-rabbit-PE, and with the appropriate anti-B7-biotin
antibody followed by streptavidin-FITC. Cells were analyzed by flow
cytometry.
doi:10.1371/journal.pone.0022772.g001
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infected in vitro with D41D29B7-1 or D41D29B7-2 was demon-
strated by flow cytometry (Figure 1C). S2 cells were mock infected
or infected, collected and stained 24 h later with anti-B7-1 and B7-
2 antibodies. Mock-infected cells or cells infected with D41D29
(Figure 1C, left panels) showed no B7 staining above background,
whereas cells infected with D41D29B7-1 or D41D29B7-2 stained
brightly for B7-1 or B7-2, respectively (Figure 1C, right panels).
These data indicate host costimulation molecules are uniformly
expressed at high levels on the surface of cells infected with
D41D29B7-1 or D41D29B7-2.
Immune response to vaccination
The capacity of B7 costimulation molecules expressed by the
immunizing virus to elicit cellular and humoral immune responses
was determined. To investigate the CD4
+ T cell response, mice
were immunized s.c. with D41D29B7-1, D41D29B7-2, the
parental ICP8
2vhs
2 virus D41D29, or an equivalent amount of
control supernatant. Six days later cells in the draining lymph
nodes were stimulated with PMA and CaI and analyzed by
intracellular staining for IFNc. All of the vaccine viruses elicited a
greater number of CD4
+ T cells producing IFNc than did control
supernatant (Figure 2A; P,0.0001 by ANOVA) but significantly,
immunization with D41D29B7-2 stimulated greater expansion of
IFNc-producing, CD4
+ T cells than did immunization with
D41D29 (Figure 2A). Because bystander activation of CD4
+ T cells
can occur in response to HSV infection [39–41], additional mice
were immunized and cells from the draining lymph nodes were
isolated 6 d later and cultured with UV-inactivated HSV-1 in an
IFNc ELISpot assay. Although the number of HSV-specific, cells
producing IFNc was lower after UV-HSV-1 stimulation than
when cells had been stimulated with PMA and CaI, immunization
with D41D29B7-2 again stimulated greater expansion of IFNc-
producing, CD4
+ T cells than did immunization with D41D29
(Figure 2B). D41D29B7-1 also appeared to stimulate more IFNc-
producing CD4
+ and CD8
+ T cells than D41D29, though the
result was not statistically significant (P,0.1).
To investigate HSV-specific CD8
+ T cell response to the
vaccine viruses, cells from the draining lymph nodes of mice
immunized as described above were cultured with peptide
representing the immunodominant CD8
+ T cell epitope gB498–
505 presented by H-2K
b [32,33,42], and were analyzed by IFNc
ELISpot. Immunization of mice with D41D29, D41D29B7-1 and
D41D29B7-2 all stimulated greater expansion of HSV epitope-
specific, IFNc-secreting CD8
+ T cells than did control supernatant
(Figure 2C; P,0.0001 by ANOVA). Significantly more CD8
+ T
cells specific for HSV were found in mice immunized with
D41D29B7-2 than with D41D29 (Figure 2C). This observation was
corroborated by analysis using tetramer staining of CD8
+ T cells
specific for the gB498–505 epitope (data not shown). D41D29B7-1
also appeared to stimulate more IFNc-producing CD4
+ and CD8
+
T cells than D41D29, though the result was not statistically
significant (P,0.1). The above data expressed as a proportion of
lymph node cells producing IFNc yielded similar results (Figure
S1). Collectively, these assays indicate stronger induction of HSV-
specific T cell responses by replication-defective viruses that
express costimulation molecules, particularly B7-2.
Stimulation of naı ¨ve CD4
+ T cells requires contact with
antigen-containing cells expressing both MHC class II and B7
costimulation molecules. To verify that MHC class II
+ cells can
express virus-encoded B7 molecules, DCs generated from the bone
marrow of B7KO mice were infected with D41D29 or D41D29B7-
2. MHC class II
+ DCs infected with D41D29 did not express B7-2
(Figure S2A, left panel). In contrast, B7-2 was detected on nearly
half of the MHC class II
+ DCs infected with D41D29B7-2 (Figure
S2A, right panel). To determine whether virus-encoded B7-2
expression had a functional consequence, CD4
+ T cells enriched
from splenocytes of DO11.10 mice were incubated with OVA and
infected B7KO DCs. The DCs infected with D41D29B7-2 and
incubated with OVA induced more pronounced CD4
+ T cell
blastogenesis than DCs infected with D41D29 and incubated with
OVA (Figure S2B). D41D29B7-2-infected DCs also stimulated
more IL-2 production by the DO-11.10 T cells (Figure S2C).
The capacity of the vaccines to elicit HSV-specific antibody was
determined by immunizing groups of mice s.c. with control
supernatant or 4610
5 pfu (high), 4610
4 pfu (medium) or
4610
3 pfu (low) doses of D41D29, D41D29B7-1 or D41D29B7-2.
Three wk after immunization, blood was collected and HSV-
specific IgG in the sera was quantified by ELISA. HSV-specific
serum antibody was generated by immunization with all of the
virus strains, but at no dose were the antibody responses elicited by
D41D29B7-1 or D41D29B7-2 significantly greater than those
induced by D41D29 (Figure 3). Subsequent experiments, however,
did show a modestly higher concentration of HSV-specific IgG in
Figure 2. IFNc-producing T cells induced by immunization. Groups of mice were immunized with 4610
5 pfu of the indicated replication-
defective virus or control supernatant. Six days after immunization cells from the draining lymph nodes were isolated. A) Lymph node cells from
BALB/c mice were stimulated with PMA and CaI, then were stained with antibodies to CD3 and CD4, permeabilized and stained with anti-IFNc and
analyzed by flow cytometry. Data represent the arithmetic mean 6 SEM of the absolute number of CD4
+IFNc
+ cells per mouse. B) Lymph node cells
from BALB/c mice were stimulated in vitro with UV-inactivated HSV-1 and analyzed in an IFNc ELISpot assay. C) Lymph node cells from BALB.B mice
were stimulated in vitro with 0.2 mM of peptide representing the CD8 epitope gB498–505 and analyzed in an IFNc ELISpot assay. Data represent the
arithmetic mean 6 SEM of the absolute number of IFNc-producing cells per mouse. Data were compiled from 3 independent experiments for each of
panels A, B and C. For each set of 3 experiments the total number of mice used was 4 to 9 mice for the control group, and 11 to 12 mice for each
vaccine group. *, P,0.05 for D41D29 compared with D41D29B7-2.
doi:10.1371/journal.pone.0022772.g002
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D41D29B7-2 virus compared with D41D29 (data not shown). The
ratio of HSV-specific IgG1 to IgG2a was approximately 1:1 in all
vaccine groups in all experiments (data not shown), indicating the
character of the humoral response was not altered by B7
expression. Thus, the moderately stronger T cell responses
induced by virus expressing costimulation molecules generally
did not manifest as significant additional help for antibody
production.
Protective effect of the vaccines
Many vaccine formulations protect when given to mice at high
doses and/or in multiple doses. We chose a more challenging test
of efficacy by giving a single vaccination with relatively low virus
doses. Groups of BALB/c mice were immunized with 4610
5 pfu
(high), 4610
4 pfu (medium) or 4610
3 pfu (low) doses of virus or
with control supernatant. At 4 wk after immunization mice were
challenged on the corneas with the virulent HSV-1 strain mP.
Replication in the corneal epithelium was quantified over the first
4 d post-challenge by titration of virus collected on corneal swabs.
Mice immunized with control supernatant experienced high levels
of challenge virus replication in the corneal epithelium (Figure 4).
All three vaccine strains reduced the amount of virus replicating in
the corneal epithelium; the high, medium or low doses of vaccine
reduced virus titers below the level observed with control
supernatant by 2, 3, or 4 d post-challenge, respectively. Interest-
ingly, immunization with the B7-1 or B7-2-expressing viruses did
not decrease virus infection in the cornea compared with D41D29
except in the high dose immunization group (Figure 4A). Even at
the high dose, the effects of B7-1 and B7-2 expression were
transient.
Blepharitis developed in mice immunized with control super-
natant by 4 d post-challenge, and became severe by 7 d post-
challenge (Figure 5). In marked contrast, all 3 replication-defective
vaccine strains protected mice very effectively from eyelid
inflammation when given at the high dose (Figure 5A).
D41D29B7-1 and D41D29B7-2 still protected mice almost
completely from blephariits at the medium dose, though
protection afforded by D41D29 appeared to wane slightly
(Figure 5B). The lowest vaccine dose did not protect mice from
blepharitis (Figure 5C). Thus, all vaccine strains provided
protection against blepharitis at the high and medium doses, but
viruses encoding either B7-1 or B7-2 did not significantly enhance
this protection over that afforded by D41D29.
Keratitis was assessed in surviving mice at 9 and 14 d post-
challenge. Most mice immunized with control supernatant did not
survive to day 9. In contrast, all mice receiving high or medium
doses of any of the vaccine viruses survived, as did most mice
receiving low dose vaccine, so these mice were evaluated for
keratitis. Each of the three vaccine strains given at the high dose
protected mice almost completely from keratitis at 9 d post-
challenge (Figure 6A), and no mouse immunized with the high
dose of D41D29B7-2 showed more than mild disease. At the
medium dose, most mice immunized with D41D29 showed
moderately severe corneal disease after HSV-1 infection. In
Figure 3. Prechallenge HSV-1-specific serum IgG titers. Groups
of BALB/c mice were immunized with low, medium or high doses of the
indicated viruses. Blood was collected 21 d after immunization and
concentration of HSV-specific IgG in serum was determined by ELISA.
Data represent the geometric mean 6 SEM compiled from 2
independent experiments for a total of 10 to 12 mice per group for
each dose. ND, not detectable (OD#wells containing PBS).
doi:10.1371/journal.pone.0022772.g003
Figure 4. Titer of challenge virus shed from the corneal
epithelium. Groups of BALB/c mice were immunized with A) high,
B) medium or C) low doses of the indicated virus or control supernatant.
All groups were challenged 1 mo after immunization by inoculation of
HSV-1 mP onto the corneas and mouse eyes were swabbed at the
indicated times post-challenge. Titers of virus collected on swabs were
determined by standard plaque assay. Data represent the geometric
mean 6 SEM for 10 to 12 samples per group at each dose, compiled
from 2 independent experiments. *, P=0.002 to 0.014 for D41D29
compared with D41D29B7-1 and D41D29B7-2. Dashed line indicates
limit of detection in the plaque assay.
doi:10.1371/journal.pone.0022772.g004
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medium dose of either B7-1 or B7-2-expressing virus (Figure 6B),
and many corneas were clear. At the lowest dose of vaccine, the
B7-expressing vaccine strains did not protect the mice from
developing keratitis better than D41D29 (Figure 6C). Results at
14 d post-challenge were very similar (Figure 6), although by this
time some of the mice in the low dose immunization groups had
died. Thus, immunizations using the medium dose (4610
4 pfu)
revealed that B7 molecules encoded by the vaccine virus
significantly enhance protection against corneal disease over that
afforded by the ICP8
2vhs
2 parental virus.
HSV-1 reaches the TG in as little as 2 d after corneal infection
unless impeded by pre-existing immunity [43–46]. We therefore
determined whether protection from keratitis afforded by
immunization with D41D29B7-1 and D41D29B7-2 viruses was
related to the level of challenge virus in the nervous system. Mice
immunized with the medium dose were chosen for analysis
because this dose had permitted the best distinction between
vaccine strains based on corneal disease. To assess acute infection
of the nervous system, groups of BALB/c mice were challenged by
corneal infection with HSV-1 4 wk after immunization, and TG
and brainstems were isolated 5 d post-challenge for determination
of virus titer. All vaccine strains protected the nervous system
compared with control supernatant. Importantly, both
D41D29B7-1 and D41D29B7-2 vaccination reduced challenge
Figure 5. Severity of blepharitis post-challenge. Mice were
immunized with the A) high, B) medium, or C) low doses of the
indicated virus or control supernatant and challenged as described in
Figure 4. Blepharitis was scored daily after challenge in masked fashion.
Data represent the mean 6 SEM for all mice compiled from 2
independent experiments (total=20 eyes for control, and 24 to 30 eyes
for each group of virus-immunized mice at each dose).
doi:10.1371/journal.pone.0022772.g005
Figure 6. Incidence of keratitis. Eyes of mice were scored in masked
fashion for signs of keratitis 9 d and 14 d post-challenge. Mean scores
are shown for groups immunized with the A) high, B) medium, or C) low
doses of the indicated virus or control supernatant. Data represent the
mean 6 SEM for all mice surviving on the indicated day and were
compiled from 2 independent experiments (total=22 to 24 eyes for
each high dose group on days 9 and 14; 28 to 30 eyes for each medium
dose group on days 9 and 14; 20 to 26 eyes for each low dose group on
day 9 and 14 to 16 eyes for each low dose group on day 14).
**, P,0.001; *, P=0.01 for D41D29 compared with D41D29B7-1 and
D41D29B7-2.
doi:10.1371/journal.pone.0022772.g006
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Encephalitis, though rare in humans, can be devastating and thus
it is important to know whether the central nervous system is
protected through vaccination. In the brainstem, D41D29B7-2
significantly reduced challenge virus replication compared with
D41D29, and both B7-expressing viruses but not D41D29 had a
significant protective effect compared with control supernatant
(Figure 7).
To determine whether the recall T cell response was associated
with decreased challenge virus replication in the nervous system,
we examined T cells in the TG and cervical lymph nodes after
challenge. Groups of BALB/c mice were immunized, subsequent-
ly infected via the cornea as described above, and mononuclear
cells infiltrating the TG were isolated 4 d post-challenge. Corneal
infection caused an influx of primarily CD4
+ T cells into the TG of
immunized mice compared with naı ¨ve controls (Figure 8A and B,
P,0.05 to 0.001). The frequency of CD8
+ T cells increased only
in the TG of mice previously immunized with D41D29B7-2
(Figure 8A and B, P,0.05 compared with naı ¨ve controls).
Significantly, previous immunization with D41D29B7-2 permitted
a greater total number of CD4
+ and CD8
+ T cells to infiltrate the
TG compared to previous immunization with D41D29 (Figure 8C).
Thus, an increase in T cell infiltration temporally coincided with
lower virus titers in the TG acutely after challenge of mice
immunized with D41D29B7-2.
To determine whether virus-specific T cells were recalled to the
ocular region by challenge virus infection, we analyzed HSV-
specific T cell responses in the draining (cervical) lymph nodes 4 d
after corneal challenge of BALB.B mice. HSV-specific CD4
+ T
cells producing IFNc were present in greater numbers in the local
lymph nodes of previously immunized mice, and a much larger
frequency (Figure S3A) and absolute number (Figure S3B) of
CD4
+ T cells was found in mice immunized with D41D29B7-2
compared with D41D29. All previously immunized mice had a
greater frequency and absolute number of HSV-specific, IFNc-
producing CD8
+ T cells in the cervical lymph nodes than did mice
immunized with control supernatant, but there was no detectable
difference among vaccine strains (Figure S3C and D). Because
these analyses were performed in BALB.B mice to monitor
gB498–505 epitope-specific CD8
+ T cells, we verified a corre-
sponding reduction in virus titer in the TG and brainstems of the
BALB.B mice immunized with B7-expressing virus (Figure S4).
Thus the nervous system was better protected by immunization
with D41D29B7-2 than with D41D29 when assessed at either 4 d
or 5 d post-challenge in BALB.B or BALB/c mice.
The capacity of vaccination to reduce establishment of latency
was determined by detection of challenge virus DNA in the TG.
Groups of mice were immunized with the medium dose of vaccine
viruses and subsequently infected on the cornea with HSV-1.
DNA was purified from individual TG 30 d post-challenge, and
their burden of challenge virus genome was determined by real-
time PCR using primers for UL50 to detect viral genomes and for
GAPDH as a normalization control. UL50 results for each mouse
were normalized to GAPDH content and the relative amounts of
UL50 were then compared between groups. The reduction in
genome load in mice immunized with either of the B7-expressing
viruses compared with D41D29 was not statistically significant
(Figure 9). The genome load in one control-immunized mouse that
survived challenge was 6 to 8-fold greater than that in mice
immunized with any of the vaccine strains (data not shown),
suggesting that all three viruses do afford some protection from
latent infection of the nervous system.
Discussion
Although long-term antiviral therapy of persons with milder
HSV keratitis has slightly reduced the clinical impact of HSK, a
vaccine is still highly desirable to prevent HSK and obviate the
need for, and side-effects and expense of, such antiviral therapy. A
viable HSV vaccine candidate must meet goals of both safety and
efficacy. Replication-defective virus vaccines address these goals
because they do not reproduce and spread in the recipient, and
they stimulate broad spectrum immune responses due to the
numerous viral proteins expressed in infected cells. Further
manipulation of prototype replication-defective viruses has
enhanced their immunogenicity and effectiveness. Using replica-
tion-defective virus, the current approach of combining vhs
deletion with virus-encoded expression of host costimulation
molecules has achieved the best protection yet against HSV-1-
induced keratitis in a mouse model. The increased efficacy of
D41D29B7-2 correlates with enhanced virus-specific CD4
+ and
CD8
+ T cell responses. D41D29B7-2 also protects the peripheral
and central nervous systems from acute infection significantly
better than the D41D29 virus lacking B7. Thus, combining vhs
deletion with provision of costimulation signals encoded from the
replication-defective virus genome further enhances T cell-
mediated immune protection, specifically against HSV-1-mediated
corneal disease and neurological infection.
The dose at which vaccines are tested can reveal their power to
protect under the most challenging conditions. Many vaccine
formulations are efficacious when given multiple times or at high
doses. Indeed, all of the vaccine strains tested herein protect
effectively against blepharitis and keratitis at an immunizing dose
of 4610
5 pfu. A single vaccination with just 4610
4 pfu of cell free
D41D29B7-1 or D41D29B7-2 revealed significantly enhanced
protection against HSK compared with D41D29. D41D29B7-2
also protected better than D41D29 against acute infection of the
nervous system. Thus, two important goals of prophylactic
vaccination to reduce or prevent disease were achieved using a
modest dose of B7-expressing, ICP8
2vhs
2 virus. Protection was
lost for all vaccine strains when given at 4610
3 pfu, but this is not
surprising considering the extremely low dose.
Figure 7. Acute replication of challenge virus in the nervous
system. BALB/c mice were immunized with the medium dose of the
indicated virus or with control supernatant and challenged by the
corneal route one month later. TG and brainstems were dissected 5 d
post-challenge, and virus titer in them was determined by standard
plaque assay. Data represent the geometric mean 6 SEM for a total of
20 TG and 10 brainstem samples per group, compiled from 2
independent experiments with similar results. **, P,0.001 compared
with D41D29. Dashed line indicates limit of detection in the plaque
assay. (P,0.001 for all virus groups compared with control supernatant
for TG; P,0.01 to 0.001 for B7-expressing viruses compared with
control supernatant for brainstem).
doi:10.1371/journal.pone.0022772.g007
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contributions to the efficacy of D41D29B7-2. The vhs deletion
may contribute more significantly to generation of HSV-specific
antibody: Immunization with D41D29 elicits a stronger antibody
response than its replication-defective parent [22], whereas B7-2
encoded by replication-defective (ICP8
2) HSV-2 [25] or
ICP8
2vhs
2 HSV-1 (Figure 3) does not as readily enhance the
antibody response. Virus-encoded B7-2, on the other hand,
contributes significantly to T cell activation after immunization
with either HSV-2 or HSV-1 B7-expressing strains (Figures 2, S2
and [25]). Interestingly, these observations indicate that the
increased T cell activation does not primarily manifest itself as
additional help for antibody production in mice that express
endogenous B7 costimulation molecules. Instead, protection
against disease and nervous system infection seen after challenge
of mice immunized with ICP8
2vhs
2 HSV-1 or ICP8
2 HSV-2
strains encoding B7 costimulation molecules correlates with the
increased numbers of IFNc-producing T cells these B7-expressing
viruses elicit (Figures 6 through 8 and [25]). Thus, while deletion
of a viral immune evasion molecule from replication-defective
HSV-1 improves vaccine efficacy [22], virally encoded B7
molecules make an additional contribution to vaccine-mediated
protection against HSK.
Figure 8. T cells in the TG in response to challenge. BALB/c mice were immunized with control supernatant or the medium dose of D41D29 or
D41D29B7-2 and challenged with HSV-1 by the corneal route one month later. TG were dissected 4 d post-challenge, pooled for each mouse, and
digested with collagenase to release mononuclear cells. CD3
+ T cells isolated from the TG were analyzed for coexpression of CD4 or CD8 by flow
cytometry. A) Representative scatter plots of T cells in the dissociated TG of mice from the indicated immunization groups. B) Percentage of CD3
+ T
cells costaining with anti-CD4 or anti-CD8. C) Total CD4
+ and CD8
+ T cells recovered from the dissociated TG of each mouse. Data were compiled from
2 independent experiments, with a total number of 4 naı ¨ve mice and 6 mice in each immunization group. *, P,0.05 to 0.01 for D41D29 compared
with D41D29B7-2.
doi:10.1371/journal.pone.0022772.g008
Figure 9. Relative levels of HSV-1 DNA in trigeminal ganglia
during latency. Groups of mice immunized with the medium dose of
virus were challenged with 8610
5 pfu HSV-1 mP 1 month later. Four
weeks after challenge, TG were removed and DNA was extracted.
Relative viral DNA content was assessed by real-time PCR using primers
for UL50 after normalization to the signal for GAPDH. Data represent
the relative mean fold decrease (6SD) of latent genome in 11 TG from
D41D29B7-1- and 11 TG from D41D29B7-2-immunized mice compared
with 11 TG from D41D29-immunized mice (set to 1). P.0.05 by ANOVA.
doi:10.1371/journal.pone.0022772.g009
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any replication-defective vaccine, on initial replication of challenge
virus is more modest. Reduced replication at the site of inoculation
typically occurs beginning 2 to 4 d post-challenge depending on
immunization dose (Figure 4 and [22]), possibly because virus-
immune T cells must be recalled from a resting state before their
activity becomes apparent. Nonetheless, HSV-1 strains expressing
B7 costimulation molecules clearly reduce corneal disease
compared with their ICP8
2vhs
2 parent (Figure 6). Mott et al.
[47] also observed that the amount of virus replication in the
corneal epithelium of mice undergoing primary infection did not
predict the incidence or severity of corneal disease. Presumably,
higher doses of vaccine virus would reduce replication of virus in
the corneal epithelium, as previously observed [22].
The mechanism underlying improved protection of the cornea
against HSK and the nervous system against infection is not
known but likely involves the D41D29B7-2-induced T cell
response. We observed an inverse correlation between virus titers
in the TG and T cell infiltration at 5 d post-challenge (Figures 7
and 8). CD4
+ T cell responses in the draining lymph node were
also enhanced just prior to tissue infiltration. Interestingly, CD8
+
as well as CD4
+ T cell numbers increased in the TG, as has been
previously observed [48,49], but unlike previous reports only the
CD4
+ T cell response was enhanced in the draining lymph node.
This may represent a difference between the recall response and
response to acute infection. Alternatively, CD8
+ T cells may
increase in the draining lymph nodes at later times post-challenge
[48]. In mice immunized with D41D29B7-1, the recall T cell
response was not quite enhanced to a statistically significant extent
relative to D41D29 but still may be sufficient to protect against
HSK better than D41D29. It must be noted that virus-specific
CD8
+ T cells also play a dominant role in suppressing HSV-1
reactivation in the TG [50,51], though a role for vaccine-induced
CD8
+ T cells in inhibiting establishment of latency has not been
demonstrated [16,51].
HSK results from the response of antigen non-specific CD8
+
and Th1 CD4
+ T cells activated during HSV infection of the
cornea of HSV-naı ¨ve mice [39–41,48]. Importantly we observed
protection of the cornea rather immunopathology in mice with
pre-existing antiviral T cell responses elicited with ICP8
2vhs
2B7
+
vaccine. Such protection has been noted with other replication-
compromised HSV or lipopeptide vaccines that elicit Th1-like
antiviral immune responses [7,9,10,14,22]. Thus, pre-existing Th1
T cells induced by vaccination that can be quickly recalled to the
cornea and TG after virus challenge must proffer a unique
advantage. These IFNc-producing, CD4
+ T cells may help protect
against HSK directly through the antiviral effects of the IFNc they
produce [52], or indirectly by limiting virus infection and
inflammation in the corneal stroma and TG, by providing an
environment rich in cytokines that reduce bystander activation,
and/or by supporting the differentiation of HSV-specific CD8
+ T
cells in response to virus vaccine [53]. A detailed analysis of T cells
and cytokines in the corneal stroma and TG acutely after
challenge of naı ¨ve versus vaccinated mice may reveal the basis
for immune-mediated protection against HSK. Regardless of the
mechanism, this protective effect has key implications for HSV-1
vaccine design because preservation of a sensitive tissue such as the
cornea is crucial to vaccine success.
D41D29B7-1 and D41D29B7-2 protect equivalently against
keratitis, but B7-2-expressing virus stimulates greater expansion of
T cells and provides better subsequent protection from acute
infection of the nervous system by HSV-1. The critical signals
mediated by B7-1 and B7-2 operate at different temporal phases of
T cell activation in response to infection. B7-2 is constitutively
expressed and rapidly upregulated for interaction with its cognate
receptor [54], whereas B7-1 expression on professional APCs must
be provoked. Despite this difference, VSV infection generates
equivalent levels of virus-specific CTL and antibody in mice
lacking either B7-1 or B7-2 [55], and immunization of B7KO
mice with HSV-2 expressing either B7-1 or B7-2 affords
equivalent protection against HSV-2 challenge [24]. Our result
that D41D29B7-2 is overall superior to D41D29B7-1 is intriguing
because B7-1 and B7-2 encoded by the vaccine viruses would be
expressed with equivalent kinetics. Perhaps in a context where
endogenous costimulation molecules are expressed, virus-encoded
B7-2 more effectively augments endogenous B7-2 signals to induce
stronger T cell activation.
Precedent exists for the beneficial activity of virus-encoded B7
costimulation molecules as a strategic element of vaccines. B7-1
and B7-2 encoded by vaccinia, adenovirus or HSV vectors
markedly augment immunogenicity of coexpressed tumor antigens
[56–58], and help reduce tumor burden in animal models [57,59–
61]. HSV strains encoding B7 costimulation molecules represent a
new direction in that they enhance the immune response to the
pathogen itself. Most viruses, including HSV, infect a variety of
cells other than professional APCs. Non-hematopoetic cells are
capable of processing and presenting viral antigen and conceivably
virus-encoded B7 costimulation molecules confer on these cells the
capacity to activate naı ¨ve T cells, thus amplifying a response that
may otherwise be limited by the inability of replication-defective
virus to spread. Noninfectious HSV particles engineered to
contain B7 costimulation molecules on their surface also induce
stronger immune responses than particles that lack B7 [62],
lending further support to the idea that B7 costimulation can be
provided exogenously in conjunction with virus antigens to
artificially create a professional APC [56,63,64]. Whatever the
mechanism, addition of B7 expression to ICP8
2vhs
2 HSV-1
confers significant protection against HSK with a single dose of
just 4610
4 pfu. Such capacity to influence disease course in mice
using very low doses of vaccine is critical as one envisions scaling
up to a vaccine dose that may be protective in humans.
Supporting Information
Figure S1 Proportion of IFNc-producing T cells induced by
immunization. Lymph node cells depicted in Figure 2 were also
analyzed based on A) percentage of CD4
+ cells stimulated with
PMA and CaI that express IFNc; B) IFNc SFC per 10
6 lymph
node cells of BALB/c mice stimulated in vitro with UV-inactivated
HSV-1; and C) IFNc SFC per 10
6 lymph node cells of BALB.B
mice stimulated in vitro with 0.2 mM peptide gB498–505. Data in B
and C represent the arithmetic mean 6 SEM per 10
6 lymph node
cells per mouse.
(TIF)
Figure S2 Virus-expressed B7 can create antigen-presenting
cells. Bone marrow cells from B7KO mice were differentiated in
vitro using recombinant mouse GMCSF and IL-4. A) CD11c
+ DCs
were analyzed by flow cytometry for MHC class II and B7-2
expression 18 hr after infection with D41D29 (left panel) or
D41D29B7-2 (right panel). B) DO-11.10 T cells were incubated for
3 d with OVA and D41D29-infected DCs (unshaded histogram) or
D41D29B7-2-infected DCs (shaded histogram) before analysis of
cell size (forward scatter of CD3
+CD4
+ T cells) by flow cytometry.
C) IL-2 produced in cultures containing DO-11.10 T cells,
OVA, and D41D29-infected DCs or D41D29B7-2-infected DCs.
A representative experiment is shown out of 3 performed.
*, P=0.0271.
(TIF)
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Groups of BALB.B mice were immunized with the medium dose
of the indicated replication-defective virus or control supernatant.
One month later mice were challenged by infected via the cornea
with HSV-1. Four days post-challenge, mononuclear cells from the
cervical lymph nodes were stimulated in vitro with A and B) UV-
inactivated HSV-1, or C and D) 0.2 mM of gB498–505 peptide
and analyzed in an IFNc ELISpot assay. Data were compiled from
3 independent experiments with UV-inactivated virus stimulus for
a total number of 8 to 10 mice per group. Data were compiled
from 4 independent experiments with peptide stimulus for a total
number of 12 to 14 mice per group. *, P,0.05 to 0.01 for D41D29
compared with D41D29B7-2.
(TIF)
Figure S4 Acute replication of challenge virus in the nervous
system of BALB.B mice. BALB.B mice were immunized with the
medium dose of the indicated virus or with control supernatant
and challenged by the corneal route one month later. TG and
brainstems were dissected 4 d post-challenge, and virus titer in
them was determined by standard plaque assay. Data represent
the geometric mean 6 SEM for 12 TG and 6 brainstem samples
per group, compiled from 2 independent experiments with similar
results. **, P,0.001; *, P,0.01 compared with D41D29. Dashed
line indicates limit of detection in the plaque assay. (For TG,
P,0.01 to 0.001 for all virus groups compared with control
supernatant; for brainstem, P,0.001 for D41D29B7-2 compared
with control supernatant).
(TIF)
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